Kathleen Borthwick - 10 Feb 2024 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Signature
/s/ Edgar Cale, Attorney-in-Fact
Issuer symbol
PASG
Transactions as of
10 Feb 2024
Net transactions value
-$1,426
Form type
4
Filing time
13 Feb 2024, 19:36:54 UTC
Previous filing
03 Jan 2024
Next filing
19 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Options Exercise +4,000 +15% 29,936 10 Feb 2024 Direct F1
transaction PASG Common Stock Sale $1,426 -1,470 -4.9% $0.9700 28,466 13 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PASG Restricted Stock Unit Options Exercise $0 -4,000 -33% $0.000000 8,000 10 Feb 2024 Common Stock 4,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.